Sp-Cyclic AMPS (sodium salt)
(Synonyms: Sp-cAMPS) 目录号 : GC11125
A cAMP derivative
Cas No.:142439-95-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sp-8-CPT-Cyclic AMPS (Sp-8-CPT-cAMPS) is a cell permeable cAMP analog that potently and selectively activates protein kinase A [1].
Protein kinase A, also known as cAMP-dependent protein kinase, is one of the most widely researched protein kinase. Protein kinase A phosphorylates proteins containing the motif Arginine-Arginine-X-Serine and activates or deactivates the proteins. Protein kinase A has been involved in regulation of glycogen, sugar, and lipid metabolism [2]. The effects of PKA activation vary with cell type. Protein kinase A has been implicated in muscular system, cardiovascular, and nervous system.
Sp-8-CPT-cAMPS is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs 8-CPT-Cyclic AMP and Sp-Cyclic AMPS. Sp-8-CPT-cAMPS is used to investigate the effects of cAMP-dependent PKA signaling [1]. In guinea-pig trachealis, treatment with 10 μM Sp-8-CPT-cAMPS for 30 min reduced the spasmogenic response with the pEC50 value of 4.74 [3].
References:
[1] Dostmann W R, Taylor S S, Genieser H G, et al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3', 5'-cyclic phosphorothioates[J]. Journal of Biological Chemistry, 1990, 265(18): 10484-10491.
[2] Hanks S K, Quinn A M, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains[J]. Science, 1988, 241(4861): 42-52.
[3] Spicuzza L, Belvisi M G, Birrell M A, et al. Evidence that the anti‐spasmogenic effect of the β‐adrenoceptor agonist, isoprenaline, on guinea‐pig trachealis is not mediated by cyclic AMP‐dependent protein kinase[J]. British journal of pharmacology, 2001, 133(8): 1201-1212.
| Cas No. | 142439-95-0 | SDF | |
| 别名 | Sp-cAMPS | ||
| 化学名 | cyclic 3',5'-[hydrogen (S)-phosphorothioate] adenosine, monosodium salt | ||
| Canonical SMILES | [S-][P@]1(OC[C@]2([H])[C@@]([C@@H](O)[C@H](N3C(N=CN=C4N)=C4N=C3)O2)([H])O1)=O.[Na+] | ||
| 分子式 | C10H11N5O5PS • Na | 分子量 | 367.3 |
| 溶解度 | ≤25mg/ml in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7226 mL | 13.6129 mL | 27.2257 mL |
| 5 mM | 0.5445 mL | 2.7226 mL | 5.4451 mL |
| 10 mM | 0.2723 mL | 1.3613 mL | 2.7226 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet